Home › Compare › ITTOF vs ABBV
ITTOF yields 2.25% · ABBV yields 3.06%● Live data
📍 ABBV pulled ahead of the other in Year 1
Combined, ITTOF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of ITTOF + ABBV for your $10,000?
ITOCHU Techno-Solutions Corporation engages in the sale, maintenance, and support of computers and network systems, software development, information processing, and support services in Japan, rest of Asia, and internationally. It offers information services-related to science and engineering; system maintenance and support services, including assembly, transfer, and installation of equipment, as well as 24-hour maintenance and systems operation services; and IT engineer training services. The company also provides IT infrastructure, business operational systems, data center operation and management, and control/management of satellite communications systems; ERP-related software development and maintenance services; satellite communications and broadcasting operation services; cloud services; and application development services. In addition, it offers sale of network and security-related equipment, storage-related devices, and software and other peripheral devices, as well as provision of IT consulting, deployment/building, and support services; and building facility operations management activities for computer centers. Further, the company is involved in the exportation of IT products; resale of hardware and software; planning, production, and maintenance of web content; planning and production of advertising media; and information gathering, research, and marketing activities. It serves telecommunication, finance, retail and distribution, public sectors and utilities, manufacturing, healthcare and medicine, transportation, and information and communications industries, as well as educational and research institutions. The company was founded in 1972 and is headquartered in Tokyo, Japan. ITOCHU Techno-Solutions Corporation is a subsidiary of ITOCHU Corporation.
Full ITTOF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.